期刊
UPSALA JOURNAL OF MEDICAL SCIENCES
卷 124, 期 4, 页码 218-227出版社
UPSALA MED SOC
DOI: 10.1080/03009734.2019.1688433
关键词
Bacteriophage; phage therapy; pharmacodynamics; pharmacokinetics; pharmacology
资金
- Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS) [221-2015-1894]
- Olle Engkvist Byggmastare Foundation [2015/419]
Clinical trial results of phage treatment of bacterial infections show a low to moderate efficacy, and the variation in infection clearance between subjects within studies is often large. Phage therapy is complicated and introduces many additional components of variance as compared to antibiotic treatment. A large part of the variation is due to in vivo pharmacokinetics and pharmacodynamics being virtually unknown, but also to a lack of standardisation. This is a consequence of the great variation of phages, bacteria, and infections, which results in different experiments or trials being impossible to compare, and difficulties in estimating important parameter values in a quantitative and reproducible way. The limitations of phage therapy will have to be recognised and future research focussed on optimising infection clearance rates by e.g. selecting phages, bacteria, and target bacterial infections where the prospects of high efficacy can be anticipated, and by combining information from new mathematical modelling of in vivo pharmacokinetic and pharmacodynamic processes and quantitatively assessed experiments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据